Cargando…

The value of comorbidities and illness severity scores as prognostic tools for early outcome estimation in patients with aneurysmal subarachnoid hemorrhage

Aneurysmal subarachnoid hemorrhage (aSAH) is a severe cerebrovascular disease not only causing brain injury but also frequently inducing a significant systemic reaction affecting multiple organ systems. In addition to hemorrhage severity, comorbidities and acute extracerebral organ dysfunction may i...

Descripción completa

Detalles Bibliográficos
Autores principales: Malinova, Vesna, Sheri, Tuzi, Kranawetter, Beate, Moerer, Onnen, Rohde, Veit, Mielke, Dorothee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663372/
https://www.ncbi.nlm.nih.gov/pubmed/36367594
http://dx.doi.org/10.1007/s10143-022-01890-5
_version_ 1784830860058427392
author Malinova, Vesna
Sheri, Tuzi
Kranawetter, Beate
Moerer, Onnen
Rohde, Veit
Mielke, Dorothee
author_facet Malinova, Vesna
Sheri, Tuzi
Kranawetter, Beate
Moerer, Onnen
Rohde, Veit
Mielke, Dorothee
author_sort Malinova, Vesna
collection PubMed
description Aneurysmal subarachnoid hemorrhage (aSAH) is a severe cerebrovascular disease not only causing brain injury but also frequently inducing a significant systemic reaction affecting multiple organ systems. In addition to hemorrhage severity, comorbidities and acute extracerebral organ dysfunction may impact the prognosis after aSAH as well. The study objective was to assess the value of illness severity scores for early outcome estimation after aSAH. A retrospective analysis of consecutive aSAH patients treated from 2012 to 2020 was performed. Comorbidities were evaluated applying the Charlson comorbidity index (CCI) and the American Society of Anesthesiologists (ASA) classification. Organ dysfunction was assessed by calculating the simplified acute physiology score (SAPS II) 24 h after admission. Modified Rankin scale (mRS) at 3 months was documented. The outcome discrimination power was evaluated. A total of 315 patients were analyzed. Significant comorbidities (CCI > 3) and physical performance impairment (ASA > 3) were found in 15% and 12% of all patients, respectively. The best outcome discrimination power showed SAPS II (AUC 0.76), whereas ASA (AUC 0.65) and CCI (AUC 0.64) exhibited lower discrimination power. A SAPS II cutoff of 40 could reliably discriminate patients with good (mRS ≤ 3) from those with poor outcome (p < 0.0001). Calculation of SAPS II allowed a comprehensive depiction of acute organ dysfunctions and facilitated a reliable early prognosis estimation in our study. In direct comparison to CCI and ASA, SAPS II demonstrated the highest discrimination power and deserves a consideration as a prognostic tool after aSAH.
format Online
Article
Text
id pubmed-9663372
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-96633722022-11-15 The value of comorbidities and illness severity scores as prognostic tools for early outcome estimation in patients with aneurysmal subarachnoid hemorrhage Malinova, Vesna Sheri, Tuzi Kranawetter, Beate Moerer, Onnen Rohde, Veit Mielke, Dorothee Neurosurg Rev Research Aneurysmal subarachnoid hemorrhage (aSAH) is a severe cerebrovascular disease not only causing brain injury but also frequently inducing a significant systemic reaction affecting multiple organ systems. In addition to hemorrhage severity, comorbidities and acute extracerebral organ dysfunction may impact the prognosis after aSAH as well. The study objective was to assess the value of illness severity scores for early outcome estimation after aSAH. A retrospective analysis of consecutive aSAH patients treated from 2012 to 2020 was performed. Comorbidities were evaluated applying the Charlson comorbidity index (CCI) and the American Society of Anesthesiologists (ASA) classification. Organ dysfunction was assessed by calculating the simplified acute physiology score (SAPS II) 24 h after admission. Modified Rankin scale (mRS) at 3 months was documented. The outcome discrimination power was evaluated. A total of 315 patients were analyzed. Significant comorbidities (CCI > 3) and physical performance impairment (ASA > 3) were found in 15% and 12% of all patients, respectively. The best outcome discrimination power showed SAPS II (AUC 0.76), whereas ASA (AUC 0.65) and CCI (AUC 0.64) exhibited lower discrimination power. A SAPS II cutoff of 40 could reliably discriminate patients with good (mRS ≤ 3) from those with poor outcome (p < 0.0001). Calculation of SAPS II allowed a comprehensive depiction of acute organ dysfunctions and facilitated a reliable early prognosis estimation in our study. In direct comparison to CCI and ASA, SAPS II demonstrated the highest discrimination power and deserves a consideration as a prognostic tool after aSAH. Springer Berlin Heidelberg 2022-11-11 2022 /pmc/articles/PMC9663372/ /pubmed/36367594 http://dx.doi.org/10.1007/s10143-022-01890-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Malinova, Vesna
Sheri, Tuzi
Kranawetter, Beate
Moerer, Onnen
Rohde, Veit
Mielke, Dorothee
The value of comorbidities and illness severity scores as prognostic tools for early outcome estimation in patients with aneurysmal subarachnoid hemorrhage
title The value of comorbidities and illness severity scores as prognostic tools for early outcome estimation in patients with aneurysmal subarachnoid hemorrhage
title_full The value of comorbidities and illness severity scores as prognostic tools for early outcome estimation in patients with aneurysmal subarachnoid hemorrhage
title_fullStr The value of comorbidities and illness severity scores as prognostic tools for early outcome estimation in patients with aneurysmal subarachnoid hemorrhage
title_full_unstemmed The value of comorbidities and illness severity scores as prognostic tools for early outcome estimation in patients with aneurysmal subarachnoid hemorrhage
title_short The value of comorbidities and illness severity scores as prognostic tools for early outcome estimation in patients with aneurysmal subarachnoid hemorrhage
title_sort value of comorbidities and illness severity scores as prognostic tools for early outcome estimation in patients with aneurysmal subarachnoid hemorrhage
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663372/
https://www.ncbi.nlm.nih.gov/pubmed/36367594
http://dx.doi.org/10.1007/s10143-022-01890-5
work_keys_str_mv AT malinovavesna thevalueofcomorbiditiesandillnessseverityscoresasprognostictoolsforearlyoutcomeestimationinpatientswithaneurysmalsubarachnoidhemorrhage
AT sherituzi thevalueofcomorbiditiesandillnessseverityscoresasprognostictoolsforearlyoutcomeestimationinpatientswithaneurysmalsubarachnoidhemorrhage
AT kranawetterbeate thevalueofcomorbiditiesandillnessseverityscoresasprognostictoolsforearlyoutcomeestimationinpatientswithaneurysmalsubarachnoidhemorrhage
AT moereronnen thevalueofcomorbiditiesandillnessseverityscoresasprognostictoolsforearlyoutcomeestimationinpatientswithaneurysmalsubarachnoidhemorrhage
AT rohdeveit thevalueofcomorbiditiesandillnessseverityscoresasprognostictoolsforearlyoutcomeestimationinpatientswithaneurysmalsubarachnoidhemorrhage
AT mielkedorothee thevalueofcomorbiditiesandillnessseverityscoresasprognostictoolsforearlyoutcomeestimationinpatientswithaneurysmalsubarachnoidhemorrhage
AT malinovavesna valueofcomorbiditiesandillnessseverityscoresasprognostictoolsforearlyoutcomeestimationinpatientswithaneurysmalsubarachnoidhemorrhage
AT sherituzi valueofcomorbiditiesandillnessseverityscoresasprognostictoolsforearlyoutcomeestimationinpatientswithaneurysmalsubarachnoidhemorrhage
AT kranawetterbeate valueofcomorbiditiesandillnessseverityscoresasprognostictoolsforearlyoutcomeestimationinpatientswithaneurysmalsubarachnoidhemorrhage
AT moereronnen valueofcomorbiditiesandillnessseverityscoresasprognostictoolsforearlyoutcomeestimationinpatientswithaneurysmalsubarachnoidhemorrhage
AT rohdeveit valueofcomorbiditiesandillnessseverityscoresasprognostictoolsforearlyoutcomeestimationinpatientswithaneurysmalsubarachnoidhemorrhage
AT mielkedorothee valueofcomorbiditiesandillnessseverityscoresasprognostictoolsforearlyoutcomeestimationinpatientswithaneurysmalsubarachnoidhemorrhage